International Clinical Trial: A Prospective, Single-Arm, Multicenter Clinical Study of Epalolitoworelimab (a PD-1/CTLA-4 Combination Antibody) Combined with Lenvatinib in the Perioperative Treatment of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128849) titled 'A Prospective, Single-Arm, Multicenter Clinical Study of Epalolitoworelimab (a PD-1/CTLA-4 Combination Antibody) Combined with Lenvatinib in the Perioperative Treatment of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma' on July 27.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Condition: High-risk localized and locally advanced clear cell renal cell carcinoma (ccRCC)

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-08-15

Target Sample Size:...